Kang Wenzhe, Zeng Hongmei, Xiong Jianping, Li Yang, Jin Peng, Shao Xinxin, Hu Haitao, Wang Bingzhi, Xie Yibin, Tian Yantao
Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
J Natl Cancer Cent. 2022 Jul 22;2(3):132-138. doi: 10.1016/j.jncc.2022.07.002. eCollection 2022 Sep.
The postoperative survival rates of patients with gastric cancer at different stages treated at the National Cancer Center (NCC) of China have not been reported. Therefore, we evaluated the survival of patients with gastric cancer who underwent surgery at the NCC from 2011 to 2018 to provide baseline information for further studies.
We identified 7,301 patients with primary gastric carcinoma who underwent surgery at the NCC between January 2011 and May 2018; among these, 5,008 patients were enrolled in this study. Follow up was completed on April 30, 2020. We analyzed the 5-year survival according to the stage, sex, age, and other clinicopathological features.
Five-year survival rates of patients with pTNM stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV treated at the NCC were 94.9%, 91.8%, 86.5%, 76.1%, 61.1%, 44.2%, 29.7%, and 8.1%, respectively, which were similar to those reported in Japan during the same period. Five-year survival rates of patients with ypTNM stages I, II, III, and IV were 93.1%, 63.2%, 27.2%, and 0.0%, respectively. In multivariable analysis, age, signet ring cell carcinoma, adjuvant chemotherapy, and degree of differentiation were revealed as important prognostic factors.
The survival rates of patients with gastric cancer treated at the NCC have been significantly improved, reaching the levels of Japan in the same period.
中国国家癌症中心(NCC)治疗的不同分期胃癌患者的术后生存率尚未见报道。因此,我们评估了2011年至2018年在NCC接受手术的胃癌患者的生存情况,为进一步研究提供基线信息。
我们确定了2011年1月至2018年5月期间在NCC接受手术的7301例原发性胃癌患者;其中,5008例患者纳入本研究。随访于2020年4月30日完成。我们根据分期、性别、年龄和其他临床病理特征分析了5年生存率。
NCC治疗的pTNM分期为IA、IB、IIA、IIB、IIIA、IIIB、IIIC和IV期患者的5年生存率分别为94.9%、91.8%、86.5%、76.1%、61.1%、44.2%、29.7%和8.1%,与同期日本报道的生存率相似。ypTNM分期为I、II、III和IV期患者的5年生存率分别为93.1%、63.2%、27.2%和0.0%。多变量分析显示,年龄、印戒细胞癌、辅助化疗和分化程度是重要的预后因素。
NCC治疗的胃癌患者生存率显著提高,达到同期日本的水平。